Immuneering (IMRX) Operating Leases (2020 - 2024)
Historic Operating Leases for Immuneering (IMRX) over the last 5 years, with Q3 2024 value amounting to $4.2 million.
- Immuneering's Operating Leases fell 663.99% to $4.2 million in Q3 2024 from the same period last year, while for Sep 2024 it was $4.2 million, marking a year-over-year decrease of 663.99%. This contributed to the annual value of $4.2 million for FY2023, which is 672.44% down from last year.
- Latest data reveals that Immuneering reported Operating Leases of $4.2 million as of Q3 2024, which was down 663.99% from $4.3 million recorded in Q2 2024.
- Immuneering's Operating Leases' 5-year high stood at $5.1 million during Q4 2021, with a 5-year trough of $481965.0 in Q3 2021.
- Over the past 5 years, Immuneering's median Operating Leases value was $4.5 million (recorded in 2022), while the average stood at $3.7 million.
- Data for Immuneering's Operating Leases shows a peak YoY increase of 84252.76% (in 2022) and a maximum YoY decrease of 1233.45% (in 2022) over the last 5 years.
- Immuneering's Operating Leases (Quarter) stood at $544767.0 in 2020, then skyrocketed by 834.51% to $5.1 million in 2021, then decreased by 12.33% to $4.5 million in 2022, then decreased by 6.72% to $4.2 million in 2023, then increased by 1.88% to $4.2 million in 2024.
- Its last three reported values are $4.2 million in Q3 2024, $4.3 million for Q2 2024, and $4.4 million during Q1 2024.